Skip to content

AASLD 2018: hepatitis B guidance

International AASLD Current

Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance

Terrault NA, et al. Hepatology. 2018;67:1560–1599
DOI 10.1002/hep.29800 · Summary checked against the source: 2026-11

Read or download the original

The AASLD 2018 guidance updated the 2016 AASLD hepatitis B guideline, adding tenofovir alafenamide (TAF) as a preferred drug. Pages are from Hepatology 2018;67(4). Use EASL 2025 for the newer European view; the main differences are summarised on the topic page.

At a glance

  1. ALT upper limit of normal for decisions: 35 U/L for men, 25 U/L for women. [p. 1569]
  2. Immune-active CHB = ALT ≥2 × ULN (or significant histological disease) plus HBV DNA >2,000 IU/mL (HBeAg-negative) or >20,000 IU/mL (HBeAg-positive). [p. 1584]
  3. Treat immune-active CHB to reduce liver complications. [Strong, Moderate · p. 1584]
  4. Preferred first-line drugs: PEG-IFN, entecavir, TDF, and TAF. Prefer TAF or entecavir with kidney or bone disease; TAF isn't for CrCl <15 mL/min or dialysis. [Strong, Low · p. 1584]
  5. Pregnancy: antiviral therapy in the third trimester if HBV DNA >200,000 IU/mL; HBIG and vaccine to the newborn within 12 hours. [p. 1567]

Preferred drugs

Drug Adult dose Notes
PEG-IFN α-2a 180 µg weekly for 1 year Flu-like symptoms, mood change, cytopenia, autoimmunity. FBC monthly to 3-monthly, TSH 3-monthly
Entecavir 0.5 mg daily (1 mg if lamivudine-exposed or decompensated) Lactic acidosis rarely in decompensation
Tenofovir disoproxil (TDF) 300 mg daily Renal tubular dysfunction, reduced bone density
Tenofovir alafenamide (TAF) 25 mg daily Less renal and bone toxicity than TDF

Adapted from AASLD 2018 Table 1 [p. 1562]

Who to screen

All pregnant women; people from countries with HBsAg prevalence ≥2%; people who inject drugs; men who have sex with men; anyone needing immunosuppression or chemotherapy; unexplained raised ALT or AST; donors; dialysis; HIV or HCV; household, needle-sharing and sexual contacts of HBsAg-positive people; health-care workers at risk; and others at risk. [p. 1564]

Clinical pearls

  • AASLD thresholds are higher than EASL: ALT ≥2 × ULN, HBV DNA >20,000 (HBeAg+) or >2,000 (HBeAg−). EASL treats at DNA ≥2,000 with any ALT rise or significant fibrosis.
  • "Normal" ALT is lower than many labs report: 35 U/L men, 25 U/L women.
  • TAF and entecavir for kidney or bone disease.

Classes and levels of evidence

How AASLD 2018 grades its recommendations. Adapted from AASLD 2018 GRADE [p. 1583]. Hover over any class or level cited on this page to see what it means.

Strength Meaning Wording used
Strong Most informed patients would choose this; benefits clearly outweigh harms
Conditional (weak) The balance is closer or uncertain; many informed patients would choose differently
Level Meaning
High quality Further research very unlikely to change confidence in the estimate
Moderate quality Further research may change confidence in the estimate
Low quality Further research likely to change the estimate
Very low quality Any estimate of effect is very uncertain

The guideline rates the quality (certainty) of the evidence as high, moderate, low or very low, and each recommendation as strong or conditional (weak). A strong recommendation means most informed patients would choose the intervention; a conditional one means many would not.